- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
STING Antibody / Stimulator of interferon genes / TMEM173 (FY13022)
Email: info@nsjbio.com
| Catalog No | Formulation | Size | Price (USD) | ||
|---|---|---|---|---|---|
|
FY13022 | Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml | 100 ug | 439 |
STING antibody detects Stimulator of interferon genes (TMEM173), a central adaptor protein in the cytosolic DNA-sensing pathway that activates type I interferon responses. The UniProt recommended name is Stimulator of interferon genes (TMEM173). This transmembrane signaling protein is critical for innate immunity, serving as a bridge between cytosolic DNA detection and antiviral gene transcription.
Functionally, STING antibody identifies a 379-amino-acid endoplasmic reticulum (ER) adaptor protein that senses cyclic dinucleotides (CDNs) generated by the DNA sensor cGAS. Upon binding to cyclic GMP-AMP (cGAMP), STING undergoes conformational changes and translocates from the ER to the Golgi apparatus, where it recruits and activates the kinase TBK1. Activated TBK1 phosphorylates IRF3, triggering transcription of interferon-stimulated genes and cytokines such as IFN-beta, establishing an antiviral state.
The TMEM173 gene is located on chromosome 5q31.2 and encodes a conserved multi-pass transmembrane protein expressed in immune, epithelial, and endothelial cells. STING signaling not only defends against viral infection but also detects self-DNA released during cellular stress, DNA damage, or mitochondrial leakage. While crucial for host defense, persistent STING activation can drive autoinflammation, tissue injury, and autoimmune disease.
STING functions as a master regulator of cytosolic DNA responses, mediating immune recognition of viral, bacterial, and tumor DNA. Gain-of-function mutations in TMEM173 cause STING-associated vasculopathy with onset in infancy (SAVI), a severe autoinflammatory disorder characterized by excessive interferon signaling. Conversely, impaired STING activation increases susceptibility to infection and impedes tumor immune surveillance. In oncology, STING serves as a therapeutic target for cancer immunotherapy, where agonists are used to boost antitumor immunity through interferon induction and dendritic cell activation.
STING antibody is widely used in immunology, oncology, and inflammation research. It is suitable for western blotting, immunofluorescence, and immunoprecipitation to detect endogenous STING protein and study its activation dynamics. This antibody supports investigations into innate immune signaling, interferon pathway regulation, and host-pathogen interactions. In cancer studies, STING detection helps evaluate immune activation following treatment with STING agonists or DNA-damaging agents.
Structurally, STING forms a homodimer with a cytosolic ligand-binding domain that interacts with cGAMP and CDNs. The protein contains four transmembrane helices anchoring it to the ER membrane and a C-terminal tail essential for TBK1 and IRF3 recruitment. NSJ Bioreagents provides STING antibody reagents validated for use in innate immune signaling, inflammation, and antiviral response research.
Optimal dilution of the STING1 antibody should be determined by the researcher.
E.coli-derived human TMEM173/STING recombinant protein (Position: L66-K347) was used as the immunogen for the STING1 antibody.
After reconstitution, the STING1 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.
Powered by Bioz